Table II.
Median overall survival, univariate and multivariate analysis according to subgroups.
| Subgroups | n | Median OS, months (95% CI) | Log rank (P-value) | Multivariate analysis HR (95% CI); P-value |
|---|---|---|---|---|
| Child-Pugh | <0.001 | 0.71 (0.59-0.84); 0.011 | ||
| A | 310 | 11.2 (10.2-12.8) | ||
| B | 63 | 3.8 (3.2-4.5) | ||
| ALBI grade | ||||
| 1 | 137 | 12.6 (10.7-18.3) | <0.001 | 1.40 (1.11-1.77); 0.005 |
| 2 | 209 | 8.8 (7.2-10.0) | ||
| 3 | 27 | 6.3 (3.3-10.1) | ||
| BCLC stage | 0.0015 | 1.02 (0.77-1.35); 0.219 | ||
| B | 97 | 14.4 (11.1-18.6) | ||
| C | 276 | 8.8 (7.5-10.1) | ||
| Vascular invasion | <0.001 | 1.31 (1.04-1.70); 0.030 | ||
| Yes | 157 | 7.2 (5.9-8.6) | ||
| No | 216 | 12.4 (10.6-15.7) | ||
| ECOG-PS | <0.001 | 0.52 (0.41-0.79); <0.001 | ||
| 0 | 196 | 18.8 (14.4-21.2) | ||
| 1-2 | 177 | 5.1 (4.6-6.4) | ||
| Neutrophils | 0.32 | |||
| Low | 186 | 10.8 (9.4-13.1) | ||
| High | 187 | 8.7 (7.1-10.1) | ||
| Lymphocytes | <0.001 | 1.22 (0.94-1.35); 0.128 | ||
| Low | 194 | 7.7 (5.3-8.8) | ||
| High | 179 | 11.9 (10.6-16.9) | ||
| Platelets | 0.334 | |||
| Low | 187 | 10.1 (8.5-11.2) | ||
| High | 186 | 9.4 (8.0-11.5) | ||
| Ascites | <0.001 | 0.74 (0.56-0.89); <0.001 | ||
| Low | 334 | 10.7 (9.7-11.9) | ||
| High | 39 | 3.5 (2.4-4.2) | ||
| NLR | <0.001 | 1.63 (1.27-2.10); <0.001 | ||
| High | 185 | 5.9 (4.4-7.4) | ||
| Low | 188 | 15.9 (12.6-18.9) | ||
| PLR | 0.002 | 1.27 (0.98-1.61); 0.137 | ||
| High | 185 | 7.6 (6.0-8.8) | ||
| Low | 188 | 12.1 (10.6-15.7) |
IQR, interquartile range; NASH, Non-alcoholic steatohepatitis; NAFLD, non-alcoholic fatty liver disease; TACE, transarterial chemoembolization; BCLC, Barceona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group.